CDKN2A and head and neck squamous cell carcinoma: Furthermore, neither HPV-status, nor TP53 mutation status26, nor CDKN2A/p16 expression levels or losses explained the differences in HNSCC sensitivity to Chk1 inhibition (Table 1 and Fig. S3d, e).